Get the Stockscreener App
58.58
0.09%
-0.05
After Hours:
58.58
Revolution Medicines Inc stock is traded at $58.58, with a volume of 406.09K.
It is down -0.09% in the last 24 hours and up +26.20% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$58.63
Open:
$58.83
24h Volume:
406.09K
Relative Volume:
0.35
Market Cap:
$9.79B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-17.97
EPS:
-3.26
Net Cash Flow:
$-551.11M
1W Performance:
+2.65%
1M Performance:
+26.20%
6M Performance:
+54.36%
1Y Performance:
+170.08%
1-Day Range:
$57.45
$59.20
1-Week Range:
$56.39
$59.72
52-Week Range:
$21.18
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
58.58 | 9.79B | 29.52M | -567.06M | -551.11M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 - GlobeNewswire
10,164 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by Advantage Alpha Capital Partners LP - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys New Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
72,030 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Eagle Asset Management Inc. - MarketBeat
Intech Investment Management LLC Purchases New Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
(RVMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Principal Financial Group Inc. Has $587,000 Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Victory Capital Management Inc. Sells 104,851 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $61.00 Average Price Target from Brokerages - Defense World
Revolution Medicines executive sells shares worth $977,508 By Investing.com - Investing.com Australia
Revolution Medicines executive sells shares worth $977,508 - Investing.com India
Revolution Medicines' SWOT analysis: stock rises on cancer drug pipeline By Investing.com - Investing.com Australia
Revolution Medicines' SWOT analysis: stock rises on cancer drug pipeline - Investing.com India
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Reaches New 12-Month HighStill a Buy? - MarketBeat
What is Wedbush's Forecast for RVMD FY2024 Earnings? - MarketBeat
HC Wainwright Issues Pessimistic Estimate for RVMD Earnings - MarketBeat
Revolution Medicines' general counsel sells $360,000 in stock - Investing.com India
Revolution Medicines Stock Soars to All-Time High of $60.53 By Investing.com - Investing.com Canada
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight - Yahoo Finance
Wellington Management Group LLP Reduces Stake in Revolution Medi - GuruFocus.com
Revolution Medicines' general counsel sells $360,000 in stock By Investing.com - Investing.com UK
Revolution Medicines Stock Soars to All-Time High of $60.53 - Investing.com
Earnings call: Revolution Medicines reports on RAS(ON) inhibitors progress By Investing.com - Investing.com Australia
Earnings call: Revolution Medicines reports on RAS(ON) inhibitors progress - Investing.com
HC Wainwright Issues Negative Outlook for RVMD Earnings - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - MarketBeat
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus.com
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Revolution Medicines Reports Q3 2024 Results and Progress - TipRanks
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress - The Manila Times
Tango Therapeutics Reports 43% Response Rate in Cancer Trial, Secures $293M Cash Runway | TNGX Stock News - StockTitan
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark A. Goldsmith sells $3.88 million in stock - Investing.com Canada
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighWhat's Next? - MarketBeat
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Revolution Medicines to Participate in Upcoming Investor Conferences - The Manila Times
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential - Investing.com India
Brokerage firm bumps Revolution Medicines stock PT on positive trial data - Investing.com Canada
(RVMD) Long Term Investment Analysis - Stock Traders Daily
Revolution Medicines (NASDAQ:RVMD) Given New $60.00 Price Target at Oppenheimer - Defense World
Revolution Medicines (RVMD) Set to Announce Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines stock hits 52-week high at $51.01 By Investing.com - Investing.com South Africa
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):